Three-year analysis of adult patients with relapsed or refractory B-cell acute lymphoblastic leukemia treated with brexucabtagene autoleucel in ZUMA-3. - Shah BD; Cassaday RD; Park JH; Houot R; Logan AC; Boissel N; Leguay T; Bishop MR; Topp MS; O'Dwyer KM; Tzachanis D; Arellano ML; et al. (Leukemia, 2025)